Skip to content

Trial Summary

To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).


AMG 650

ACTRN/NCT /ethics:


Scientific title:

A Phase 1, Multicenter, Open-label, Dose-Escalation and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors (protocol number 20190131).

Sponsor / Cooperative group:


Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2020-03-11
Anticipated End Date2024-07-02

Participating Hospitals

HospitalThe Queen Elizabeth Hospital
Clinical Trial CoordinatorPamela Cooper
Phone08 8222 6140
Principal InvestigatorDr Amanda Townsend
Recruitment StatusRecruiting